Godavari Biorefineries Limited strengthened its intellectual property portfolio in life sciences by securing a United States patent for its invention titled “5-Hydroxy-1,4-Naphthalenedione for Use in the Treatment of Cancer.” The latest grant extends the company’s patent protection beyond India, China and Japan, reinforcing its research focus on compounds with potential applications in cancer treatment.
US Patent Expands Godavari Biorefineries’ Global IP Portfolio
The newly granted US patent covers a class of compounds being investigated for their ability to inhibit cancer cells and cancer stem cells. According to the company, the research indicates potential applications across several cancer types, including breast and prostate cancer. Furthermore, the patent strengthens Godavari Biorefineries’ international intellectual property presence in life sciences and supports its ongoing efforts to explore novel approaches to cancer treatment.
Company Highlights Commitment to Human Health and Innovation
Samir Somaiya, Chairman and Managing Director of Godavari Biorefineries Ltd, said, “Our approach to innovation is guided by a larger purpose: advancing human health and wellbeing. The Sanskrit mantra ‘सर्वे सन्तु निरामयाः’, meaning ‘Health for All’, reflects this commitment. The grant of this US patent marks an important milestone in our life sciences research, strengthening our intellectual property and advancing our work on compounds with potential applications in cancer treatment. It reinforces our belief that scientific progress should strive to make better health and wellbeing accessible to all, contributing to a healthier future for everyone.” He emphasised that the patent reflects the company’s broader commitment to scientific research and the development of potential healthcare applications.
Research Focuses on Cancer Cells and Cancer Stem Cells
Dr Sangeeta Srivastava, Executive Director of Godavari Biorefineries Ltd, highlighted the importance of sustained scientific research in developing novel molecules for potential cancer treatments. She said, “The development of novel molecules for potential applications in cancer treatment requires sustained scientific research and a deeper understanding of the mechanisms involved in cancer cell growth. This patent represents an important step in our research journey, particularly in exploring compounds that target cancer and cancer stem cells. Our focus remains on advancing scientific understanding and building on our research capabilities to explore potential approaches to complex human health challenges.” Her comments underscore the company’s focus on understanding cancer cell growth and investigating compounds that could contribute to future therapeutic approaches.
Four Researchers Named as Patent Inventors
Dr Sangeeta Srivastava is one of the four inventors named in the patent. The other inventors are Dr Sandip Gavade, Dr Prashant Kharkar and Dr Maithili Athavale. The US patent adds to Godavari Biorefineries Ltd’s existing intellectual property in life sciences and further strengthens its research portfolio in cancer-related applications.
Patent Milestone Strengthens Life Sciences Research
The latest patent grant marks another step in Godavari Biorefineries’ efforts to expand its life sciences research and protect its scientific innovations across international markets. As per the press release, while further research and development will determine the compound’s potential therapeutic applications, the patent strengthens the company’s intellectual property position and supports its long-term focus on exploring innovative approaches to cancer treatment.
